Evidence map›Paper›PMID 40430032›Full record

ReviewInternational journal of molecular sciences2025

Promising Vaccine Formulations for Emerging Infectious Diseases.

Pil-Gu Park, Seok-Yong Lee, Hyewon Youn, Kee-Jong Hong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pil-Gu ParkDepartment of Life Science, Gachon University, Seongnam 13120, Republic of Korea.ORCID 0000-0002-3024-3439
Seok-Yong LeeDepartment of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.ORCID 0009-0001-6381-5683
Hyewon YounDepartment of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.ORCID 0000-0003-1006-2689
Kee-Jong HongDepartment of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences & Technology (GAIHST), Gachon University, Incheon 21999, Republic of Korea.ORCID 0000-0003-2054-7014

Funding

Ministry of Food and Drug Safety 22213MFDS421Ministry of Food and Drug Safety HI22C0009Ministry of Food and Drug Safety HV22C0004Ministry of Food and Drug Safety RS-2023-00217026Ministry of Food and Drug Safety RS-2024-00331833National Research Foundation of Korea NRF-2020R1A2C2011695
6 · The paper itself

Abstract

Emerging infectious diseases (EIDs) are one of the greatest threats to human health today, thus requiring an urgent response. Vaccines are one of the most effective means of preventing the spread of infectious diseases, and their usefulness in responding to EIDs has been clearly proven through the process of overcoming the global COVID-19 pandemic. As the characteristics of various vaccine formulations differ, it is necessary to apply the most appropriate one according to the EID response strategy. In this review, we first consider which vaccine formulation is the most suitable for EID vaccines by comparing the pros and cons of different vaccine formulations, and then we discuss the utility of mRNA vaccine formulations, which are considered the most promising for EID vaccines.

Indexed as

Communicable Diseases, EmergingCOVID-19COVID-19 VaccinesHumansSARS-CoV-2COVID-19 Vaccinesemerging infectious disease (EID)mRNA vaccinevaccine formulation

Identifiers

PMID40430032
PMCPMC12112343

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.